Learning Objectives:

1.    To identify the most common dermatologic reactions to immune checkpoint inhibitors.
2.    To discuss how to treat common dermatologic reactions to immune checkpoint inhibitors, including rash and pruritus.
3.    To discuss steroid-sparing alternatives to treatment of dermatologic reactions to immune checkpoint inhibitors

Disclosures:

Jennifer Choi, MD, Presenter, is on the Medical Advisory Board for Bristol Meyers Squibb.

Faculty member does plan on discussing unlabeled/investigational uses of a commercial product: aprepitant, dupilumab, methotrexate, cyclosporine, etanercept, and gabapentin.